Quantcast

Industry news that matters to you.  Learn more

Definiens to Host the First International Symposium for Tissue Phenomics This Fall

Definiens, the global leader in Tissue Phenomics™ for oncology diagnostics, recently announced that registration is now open for the company’s inaugural conference, The International Symposium for Tissue Phenomics. Alongside genomics, Tissue Phenomics is a key driver in the growth of personalized medicine, and the symposium brings together thought leaders from around the globe on companion diagnostics, immunotherapy, and tissue-based patient stratification for personalized medicine. The Symposium will begin with a keynote lecture from Nobel Laureate, Gerd Binnig, Ph.D., discussing his approach to uncovering novel diagnostics through using big data in tissue.

Restore Launches Pharmacogenetic Testing

Restore Health, a leading personalized medicine company that provides specialty and compounded pharmaceuticals, announced that it is now offering pharmacogenetic testing that provides drug sensitivity information unique to each individual based upon their particular genetic makeup. Comprehensive medication management is now possible by understanding the interaction between a patient’s genetics and their entire drug regimen.

IBM, Coriell Life Sciences and CareKinesis Deliver Personalized Medicine to the Elderly Via the Cloud

IBM (NYSE: IBM) recently announced a collaboration with Coriell Life Sciences, a provider of genetic analysis at point of care, and CareKinesis, Inc., a Medication Risk Mitigation® pharmacy services firm, to bring personalized medicine to the elderly based on analyzing and storing genetic data in a secure cloud environment.

The Swedish Cancer Institute Launches Personalized Medicine Program

The Swedish Cancer Institute (SCI) recently announced its new Personalized Medicine Program that combines advanced medical treatments based on the unique, molecular signature of a patient’s cancer with supportive care that is designed to serve each individual’s physical and emotional health.

EMA Scientific Advice for Lybrido and Lybridos Endorses Company Proposals

On January 29th, 2014, Emotional Brain received the Scientific Advice letters from the European Medicines Agency (EMA) for the products Lybrido and Lybridos. The company is very pleased to announce that virtually all company proposals on the development plans for the two products were endorsed.